Decoding biology demands a bold approach
Eroom’s Law
Drug discovery is becoming slower and more expensive over time
The biopharmaceutical industry faces pressure amidst declining efficiency in drug discovery.
Moore’s Law
Meanwhile computing power is becoming faster and less expensive over time
The biopharmaceutical industry has historically lacked the tools to understand biology’s complexity.
The opportunity
Recursion is leveraging technology to industrialize drug discovery
Recursion was founded to take advantage of the discontinuity between these fields and harness the power of accelerating technological innovations to improve the efficiency of drug discovery and development.
.svg)
From BioTech to TechBio
Our automated wet labs and dry labs – powered by a world class supercomputer – collect, model, and analyze fit-for-purpose data and perform in silico experiments. Our machine learning models identify the most promising targets, and are continuously and exponentially improving.
Mapping biology
Our Maps of Biology uncover novel insights from millions of wet lab experiments and other data layers, including phenomics, genomics, transcriptomics, and patient data.
Traditional approach is slow and costly
Traditional drug discovery focuses narrowly on one target, with a significant investment – multiple years and millions of dollars – to determine its viability.
Reshaping drug discovery from V to T
We’re improving cost, timelines, and efficiency by taking an unbiased, disease-agnostic approach. Our Maps of Biology allow us to evaluate new programs in bulk, and prioritize novel opportunities with high unmet need.
Traditional approach is slow and costly
Traditional drug discovery focuses narrowly on one target, with a significant investment – multiple years and millions of dollars – to determine its viability.
~ One potential program
Hundreds of potential programs evaluated; we choose the best
Reshaping drug discovery from V to T
We’re improving cost, timelines, and efficiency by taking an unbiased, disease-agnostic approach. Our Maps of Biology allow us to evaluate new programs in bulk, and prioritize novel opportunities with high unmet need.
Traditional approach is slow and costly
Traditional drug discovery focuses narrowly on one target, with a significant investment – multiple years and millions of dollars – to determine its viability.
Reshaping drug discovery from V to T
We’re improving cost, timelines, and efficiency by taking an unbiased, disease-agnostic approach. Our Maps of Biology allow us to evaluate new programs in bulk, and prioritize novel opportunities with high unmet need.
Traditional approach is slow and costly
Traditional drug discovery focuses narrowly on one target, with a significant investment – multiple years and millions of dollars – to determine its viability.
~ One potential program
Hundreds of potential programs evaluated; we choose the best
Reshaping drug discovery from V to T
We’re improving cost, timelines, and efficiency by taking an unbiased, disease-agnostic approach. Our Maps of Biology allow us to evaluate new programs in bulk, and prioritize novel opportunities with high unmet need.
Turning drug discovery into a search problem
We're generating new programs in unexplored areas of biology with high disease relevance in an efficient and repeatable way, creating a feedback loop that means our predictions are constantly improving.
REC-1245 case study
From target ID to IND-enabling studies in <18 months.
.png)
.png)
.png)
